UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., which would lead to Tevogen holding a majority voting interest in Sciometrix if completed [1][2]. Group 1: Potential Transaction - The transaction aims to enhance Tevogen's capabilities and transition it into a revenue-generating healthcare enterprise by integrating Sciometrix's digital care management platform, Clinicus, and remote patient monitoring technologies with Tevogen.AI [2][11]. - Sciometrix has achieved significant milestones, becoming one of the top 25 digital healthcare companies in the USA, and aims to break into the top 10 with the integration of Tevogen.AI [2]. - The proposed transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2]. Group 2: Company Background - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms to develop advanced therapies across multiple areas [4]. - Tevogen Bio has completed a proof-of-concept clinical trial for its T cell therapy, with a pipeline that includes virology, oncology, and neurology [5]. - Tevogen.AI aims to transform drug development by improving target detection and clinical trial design through predictive technologies [6]. Group 3: Future Initiatives - Tevogen is exploring additional strategic initiatives in life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions [3][7].